Results from a first-in-human phase 1B study of a complement factor H inhibitor (GT103) in patients with non-small cell lung cancer (NSCLC)Jeffrey Melson Clarke,Tom Stinchcombe,Lin Gu,Hirva Mamdani,Scott Joseph Antonia,George R. Simon,Guru P. Sonpavde,Neal E. Ready,Jeffrey Crawford, Michael Campa,Elizabeth Gottlin, Ryan Bushey,James Emmett Herndon,Edward PatzJOURNAL OF CLINICAL ONCOLOGY（2023）引用 0|浏览17暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
